Teva Pharmaceutical Industries Limited (TLV:TEVA)
9,385.00
+55.00 (0.59%)
Apr 6, 2026, 2:24 PM IDT
TLV:TEVA Revenue
In the year 2025, Teva Pharmaceutical Industries had annual revenue of $17.26B USD with 4.32% growth. Teva Pharmaceutical Industries had revenue of $4.71B in the quarter ending December 31, 2025, with 11.40% growth.
Revenue
$17.26B
Revenue Growth
+4.32%
P/S Ratio
1.95
Revenue / Employee
$525.49K
Employees
32,842
Market Cap
107.44B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Danel (Adir Yeoshua) | 2.90B |
| Novolog (Pharm-Up 1966) | 1.81B |
| Ilex Medical | 930.83M |
| Kamada | 575.31M |
| SofWave Medical | 279.39M |
| BrainsWay | 166.49M |
| Bait Bakfar | 109.62M |
| Golden House | 46.05M |
Teva Pharmaceutical Industries News
- 8 days ago - Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31 - GuruFocus
- 9 days ago - Teva (TEVA) Advances with Biosimilar Application Review for Xolair - GuruFocus
- 9 days ago - FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar - GuruFocus
- 9 days ago - Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30 - GuruFocus
- 9 days ago - Notable ETF Outflow Detected - FNDF, MDT, ZIM, TEVA - Nasdaq
- 9 days ago - Teva Secures FDA Nod For PONLIMSI, Biosimilar Candidate To Xolair Applications Accepted By FDA & EMA - Nasdaq
- 9 days ago - Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab) - GlobeNewsWire
- 20 days ago - Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA) - GuruFocus